Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model.
Why this byte is shareable
Signal quality
observed
Confidence badge and source context included.
Entity anchor
AI News
Clear company or model context for distribution.
Export ready
1200 x 630 card
Optimized for X, LinkedIn, and chat previews.
Why it matters
AI News can change capability, routing, cost, or product scope for builders shipping against current model APIs.
Suggested launch post
Use this in X threads, community posts, internal team chats, or launch recaps.
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model Why it matters: AI News can change capability, routing, cost, or product scope for builders shipping against current model APIs. Source: Financial...
Permalink: https://a2zai.ai/bytes/tempus-and-recursion-extend-existing-data-license-agreement-and-enter-new-licens-32448523
Social card: https://a2zai.ai/bytes/tempus-and-recursion-extend-existing-data-license-agreement-and-enter-new-licens-32448523/opengraph-image